ePoster

All ePoster presentations will be available to view anytime throughout the Meeting in an Online Library

Title:

Sympathetic ophthalmia: a case report

Poster Details

First Author: I. Hasnaoui MOROCCO

Co Author(s):    E. Abdellah   B. Chaimae   S. Hassina   l. robbana   B. Amina        

Abstract Details

Purpose:

Sympathetic ophthalmia is a bilateral, diffuse granulomatous uveitis that usually occurs after penetrating eye trauma or surgery. The time interval between the onset of symptoms and the trauma varies from a few days to several years. Its estimated incidence is 0.3-0.5% in eye trauma and 0.015% in eye surgery. Early diagnosis and adequate therapeutic management are necessary in order to improve the prognosis of this condition.

Setting:

ophthalmology B Department ibn Sina university hospital (speciality hospital ), Rabat, Morocco

Methods:

We report the case of a 27-year-old patient, left eye monophthalm, right eye lost by a perforating trauma 15 years ago, who presented with a red and painful left eye , floaters with reduced visual acuity dating back to 45 days , the patient brings back the notion of red and painful eye repeatedly.

Results:

The visual acuity was reduced on hand motion in the left eye , and no light perception in the right eye that was in phtyse. the examination of the left eye showed posterior uveitis, posterior polar cataract with sequelae of anterior uveitis(keratic precipitates, including the mutton fat keratic precipitates,Vitritis,Dalen-Fuch nodules..).no other cause of granulomatous uveitis was found, the diagnosis of sympathetic ophthalmia was made. our patient was treated with systemic corticosteroid therapy, and cyclophosphamide.acuity changed from hand motion to 1/10 over a 4-year follow-up. The eye remained calm and there was no recurrence after stopping treatment.

Conclusions:

Sympathetic ophthalmia presents a challenge for the ophthalmologist in all its aspects, especially with regard to his exclusionary diagnosis; the severity of the clinical picture and the cost of treatment, which must be initiated as early as possible in order to improve the visual prognosis.

Financial Disclosure:

None